Stem, Inc. (NYSE: STEM - Get Free Report) has received a consensus recommendation of "Reduce" from the five ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average twelve-month price target among brokerages

Darmstadt, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- Employee volunteer program brings hands-on science learning to communities worldwide More than 600.000 students reached and nearly 200.000 employee volunteer hours  Ambitious 2035 goals aim to double student reach and expand global impact Merck, a leading science and technology company, marks the 10th anniversary of SPARK™, its global employee volunteer program that connects employees with communities through hands-on science learning and local service. For the past decade, SPARK™ has helped bring science to life for students through interactive experiences, classroom learning, and community partnerships, powered by employees who volunteer their time, expertise, and enthusiasm.

Stem has seen its multiple to annual recurring revenue dip to 1.64x on the back of a sustained pullback in its common shares. The company saw its GAAP and non-GAAP gross profit margins at 49% and 45%, respectively. Fiscal 2025 was the first year STEM's non-hardware revenue constituted the majority of its sales.

Stem, Inc. (STEM) Q4 2025 Earnings Call Transcript

Stem, Inc. (STEM) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $1.96. This compares to a loss of $2.4 per share a year ago.

HOUSTON--(BUSINESS WIRE)--Stem announces Q4 and full year 2025 results, achieving first-ever positive Adjusted EBITDA with record margins.

BERLIN--(BUSINESS WIRE)--Stem's PowerTrack™ EMS selected for 100 MWh of utility-scale storage in Germany, expanding its European footprint.

HOUSTON--(BUSINESS WIRE)--Stem, Inc. (NYSE: STEM), a global leader in AI-enabled clean energy software and services, will hold a conference call on Wednesday, March 4, 2026, to discuss its financial results for the fourth quarter and full year ending December 31, 2025. The conference call is scheduled to begin at 5:00 p.m. Eastern Time. A press release regarding the results will be issued at approximately 4:05 p.m. Eastern Time. The conference call may be accessed via a live webcast on a listen.

Winter Park, Florida--(Newsfile Corp. - January 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its subsidiary Adia Med of Winter Park, LLC, today highlighted key details of its ongoing IRB-approved clinical study for children with Autism Spectrum Disorder (ASD), listed on ClinicalTrials.gov (NCT07304440). The trial ensures every participating child in Phase One or Phase Two receives umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) three times, administered monthly during the initial three-month interventional phase, combined with glutathione in the experimental arm to evaluate potential improvements in ASD symptoms.

The energy storage sector sits at the intersection of renewable energy expansion, grid modernization, and electrification.